RCS - Solvonis Therapeutic - Presentation at PharmaSynergyRx Event

Solvonis TherapeuticsAnnouncement

25/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250225:nRSY2530Ya&default-theme=true

RNS Number : 2530Y  Solvonis Therapeutics PLC  25 February 2025

RNS Reach - non-regulatory announcement

25 February 2025

Solvonis Therapeutics plc

("Solvonis Therapeutics" or the "Company")

 

Solvonis Therapeutics - Advancing Treatments for Mental Health and Addiction

 

Solvonis Therapeutics (LSE: SVNS), an innovative biotechnology company
co-developing therapeutics for mental health disorders, announces that
Anthony Tennyson, Chief Executive Officer of the Company, will be presenting
Solvonis Therapeutics plc in the Strategy and Growth track at the
PharmaSynergyRx 2025 event in London on 27 February 2025.

 

PharmaSynergyRx brings together over 200 Business Development and C-suite
executives, creating a platform for companies pursuing co-developments,
partnerships, licensing and commercial deals within the bio-technology
industry.

 

For more information, please visit:
https://pharma-synergy-conference.com/pharmasynergy-2025/
(https://pharma-synergy-conference.com/pharmasynergy-2025/)

 

Enquiries:

 

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

Email: anthony@solvonis.com

 

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on
developing intellectual property related to the treatment of mental health and
substance use disorders, and co-developing therapeutics for mental health
disorders. Solvonis' mission is to improve outcomes for individuals suffering
from mental health disorders, with an initial focus on trauma-related mental
health conditions, such as PTSD. PTSD affected approximately 13 million adults
in the U.S. in 2020, with the Company estimating a current affected population
of 20 million across the U.S., UK, and key EU markets.

 

www.solvonis.com (http://www.solvonis.com) | LinkedIn
(http://www.linkedin.com/company/solvonis) | X (formerly Twitter)
(https://x.com/SolvonisTx)

 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGZZKDKGKZM